Just a thought...I warned this board many times about following or paying Seth for advice. Possible one of the worst traders or investors over the last 4 years...Have I made bad trades? sure, however Seth has continued to give bad advice to paid suckers. I'm up well over 550% over the last 3 years? Seth? Just check out his calls..You are up (maybe slightly), but he has yet to bet the S and P 500 since he began scamming people.
Well I've watch him for years using slight of hand (example: don't follow me (today)). Which means follow me and look at me...all leading to getting your Visa out and paying him $39.99 for advice on how to lose money fast. I consistently said Soda's CEO was a joke and now look? He's a joke and the court Jester? You guessed it, Seth and his lies.
I leave you all to clean this mess up...As for me my last couple thousand shares sold for a $3200 loss...But I can make that up. However, the guys who got scammed by this thief will more than likely never get their money back. Lastly, thank-you Soda, I made well over 6 figures (only long) on your dream and I'm sorry how you may fade away in a slow death, but only hope is you take that nut with you. Peace.
Best to all longs...
Volume and the charts are on the long side for once...
High volume we go up...No volume and low volume our MM's just play games.
After camping out here for years it sure looks like we are going to make a huge run...
Others Gnvc @ 2.30 (10,000 common/trimmed 4,000 @4.24)
Just re-bought Gale...Chart looking good
Ambs-Talk about a spec
Just bought opxa...Pre-Secondary
Ormp- Bought right here 4,000 common @ 4.55
Yes, Thank you. Now leave....You don't sell shares because of Secondary/Warrants Etc...Nothing has change in their pipeline. You keep your bullets in your gun and wait to buy more and load up. I'm ready for the run up..
All you need to know is the charts. Forget about the fact that our number one drug is going mainstream soon.
Thanks for your shares...I was wondering who sold me their common (3500) shares in the morning session. That leaves me at 12,500 common. Best, young pup. We are now moving up from left to right. And you will not be missed. Now leave.
Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Threshold Pharmaceuticals (NASDAQ: THLD) to $15.00 (from $13.00) saying a Hypoxia driven pipeline could emerge in 2015.
Duncan commented, "We recently caught up with Threshold because we believe 2015 could prove transformational for the company. Due to 2015 likely yielding multiple pivotal trial readouts and increased visibility on a wholly-owned but as yet under the radar-screen program that could take a run at higher profile TKi lung cancer programs, we would now include THLD as a top-pick small cap, under-discovered OncoInnovator. The key events of note in 2015 may be data (event driven) from the Phase IIIs for TH-302 in soft tissue sarcoma (STS) and pancreatic cancer. These are likely YE15 or early-'16 events but recent data in STS enhance our conviction that the study design could result in approvable and clinically significant benefit of 25-35% increased OS in this SPA-backed trial."
For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.
Shares of Threshold Pharmaceuticals closed at $3.52 yesterday.
He gets two cents for each negative post he writes...The fact that some of the posts have correct spelling and grammar is outstanding. We all (fellow doctors at the his home) are so proud of all the progress he has made.
Go Johnny, Go.
You asked me if I was green or Red. Excuse me for providing context to your question...My comments to you on this board are made because you simply add no value to the conversation. You are simply negative on Rnn for the sake of being Negative. Your conclusions have to fact based thesis around them...Just random thoughts racing through that whole in your head. Have fun in S. California I just got back. Stayed at the Marriott in Anaheim. I'm done as you are boring me now...Best to all longs.
I sold out my 55,000 common at an avg. cost of $1.56. Started my new position at 1.02/ through .67. My avg. cost is .79 PPS. Your statement of you don't take people seriously if they stated their positions is with out a doubt the dumbest thing you have stated.
Very funny action...We are so controlled by the big boys...
Maybe? However, if you mix a secondary with some good news/results and etc...the effect can be positive. I've bought plenty of bio's at the 1.50 pps secondary price and watch them roll up to 6.00/7.00 pps. Best.
And Toppy, seek help...
I told the board on last Thursday...She's about to blow upwards. OPXA another reasonable spec (risk/reward).
As for Toppy, he's simply lying like a crazy man in NY on the the street.
Roth Capital affirms GenVec (Nasdaq: GNVC) at Buy with a price target of $8 following a recent update from management.
Analyst Joseph Pantginis sees 2015 as being a potentially transformative year for GenVec. The analyst commented, GenVec has been running lean operations with two primary ongoing activities:
1) providing background support to Novartis for the hearing loss program; and
2) continuing its internal efforts to progress and potentially monetize its proprietary adenoviral platform, namely vaccine candidates.
Pantginis continued, We believe 2015 could be quite an interesting year for GenVec. For the NVS hearing loss program media attention and importantly, focus on the Novartis website continue to fuel excitement in the program in our belief. With patients already having been dosed we are now entering a time where NVS is deciding how to show its hand should any efficacy be seen. Recall the doses being used are thought to be therapeutic based on animal model data. The balancing act being played revolves around announcing transformational data for hearing loss and building a robust data set for future regulatory filings (if successful).
For an analyst ratings summary and ratings history on GenVec, Inc. click here. For more ratings news on GenVec, Inc. click here.
GenVec, Inc. closed at $3.55 yesterday.
Bid and Ask now with-in a penny. We are in the 90 percent chance of moving out and taking out our 52 week high. Next week should be fun. Gale/Rnn all looking good.